Avid Bioservices Inc (CDMO)

[entdoc]

James GMS. Agree that + or - 2 months (or similar) of additional survival for advanced lung cancer might be a marketable product for a large pharma, but when you have zero marketing staff such as PPHM, it is doubtful. For instance, would you believe not one in a hundred, or even a thousand oncologists has heard of PPHM or Baxituximab? How do you get word out there? Imagine the insurance company reaction to a product that costs thousands of dollars and extends life by a few statistically significant days. The insurance industry would label it experimental/investigational, and refuse to pay for it. That scenario is real life. Maybe a large pharma could pull it off, but again, as we've seen, not a small Pharma like PPHM. PPHM beat the standard of care in glioblastoma multiform with Cotara, but Cotara is on the shelf. I repeat: Bavituximab is a very good/promising molecular construct still in search of an application, and it is not advanced solid cancers.